$0.95▾ 26.02%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$60.37MTTM operating cash
Pre-profit
It generates operating cash even though it has no reported profit yet.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
-6.6%year over year
Weak
Revenue is contracting year over year.
Leverage
Lowdebt to assets
Strong
Very low debt relative to its asset base.
More coming: dilution / share-count creep.
Fair value
Fairly valued
Trading right around our fair-value range
Balance-sheet caution
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Akebia Therapeutics, Inc. is pre-profit. It generates operating cash even though it has no reported profit yet. Revenue is contracting year over year. Very low debt relative to its asset base.
Key numbers
Valuation
EPS (TTM)$-0.08
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-8.8%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$232.40M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.